Acetylsalicylic acid on primary prevention of cardiovascular diseases

Abstract

Get full access to this article

View all access options for this article.

References

Lettino

Leonardi

De Maria

et al.

Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease. Eur J Prev Cardiol 2017; 24(3 Suppl.): 61–70.

Fox

Golden

Anderson

et al.

American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research; American Diabetes Association. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2015; 132: 691–718.

Proietti

Mairesse

Goethals

et al.

Cerebrovascular disease, associated risk factors and antithrombotic therapy in a population screening cohort: insights from the Belgian Heart Rhythm Week programme. Eur J Prev Cardiol 2017; 24: 328–334.

Khedri

Szummer

Carrero

J-J

et al.

Systematic underutilisation of secondary preventive drugs in patients with acute coronary syndrome and reduced renal function. Eur J Prev Cardiol 2017; 24: 724–734.

Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research; American Diabetes Association. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2015; 132: 691–718.

Piepoli

Hoes

Agewall

et al.

ESC Scientific Document. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315–2381.

Antithrombotic Triallists’ (ATT) Collaboration Baigent

Blackwell

Collins

et al.

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–1860.

Upadhaya

Madala

Baniya

et al.

Impact of acetylsalicylic acid on primary prevention of cardiovascular diseases: a meta-analysis of randomized trials. Eur J Prev Cardiol. 2019; 26: 746–749.

Xing

Shi

Zhu

et al.

How aspirin prevents cardiovascular diseases. Eur J Prev Cardiol 2018; 25: 640–640.

10.

Patrono

. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287–1294.

11.

Patrignani

Patrono

. Aspirin and cancer. J Am Coll Cardiol 2016; 68: 967–976.

12.

ASCEND Study Collaborative Group Bowman

Mafham

Wallendszus

et al.

Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018; 379: 1529–1539.

13.

Gaziano

Brotons

Coppolecchia

et al.

ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392: 1036–1046.

14.

Mattioli

Manenti

Farinetti

. Sex differences in adherence to guidelines in aspirin prescription in a population of low-risk cardiovascular patients. Eur J Prev Cardiol 2018; 25: 606–607.